Clinical Trial Update: A Clinical Trial of Durvalumab (MEDI4736) as 1st Line Therapy in Advanced Non-small Cell Lung Cancer Patients [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating durvalumab (MEDI4736) as first-line therapy in advanced non-small cell lung cancer has completed with results posted in 2023…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Durvalumab (durvalumab)

Snippet

Sponsor: Academic Thoracic Oncology Medical Investigators Consortium | Conditions: Non-Small Cell Lung Cancer NSCLC | Phase 2 | Status: COMPLETED | Results posted: 2023-10-24